We would like to share our opinion on the publication “Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios.”1 A study that included 1,500 workers was conducted in the Health Department of Orihuela, Alicante (Spain) to measure the presence of neutralizing antibodies prior to the administration of a third vaccine dose. Demographic variables were collected and an immunochromatography test was performed using the OJABIO® SARS-CoV-2 neutralizing antibody detection kit. The results showed that 38.5% of the participants had neutralizing antibodies, with important predictive factors being time since the last vaccine dose and previous SARS-CoV-2 infection.

Only 64% of workers had complete information, which may have introduced selection bias and affect the ability to extrapolate the results. The study did not provide information on the specific characteristics of participants who tested positive for neutralizing antibodies, which limits the understanding of factors that influence the presence of antibodies. The study did not investigate other potential factors that may have an influence on the presence of neutralizing antibodies, such as the vaccine type or underlying health conditions.

For future guidance, the participation rate should be increased to ensure a more representative sample of the workforce. Furthermore, detailed information on the characteristics of participants with neutralizing antibodies should be included in order to identify potential trends or risk factors. In addition, it should be considered whether to explore additional factors that may influence the presence of antibodies, such as the type of vaccine, comorbidities, or variations in the immune response.